Next |
home / stock / moc / moc message board
Subject | By | Source | When |
---|---|---|---|
I hope this sale provides some additional contracts. | cj 13 | investorshub | 09/20/2018 1:04:35 AM |
* * $MOC Video Chart 08-02-18 * * | ClayTrader | investorshub | 08/02/2018 9:34:56 PM |
MOC share price looks like it's trying to | cj 13 | investorshub | 03/09/2018 3:12:29 PM |
29 percent year to year. Think the next | cj 13 | investorshub | 06/19/2017 5:50:21 PM |
I agree. I am definitely going to buy | Cboneofenglewood | investorshub | 06/18/2017 3:39:27 AM |
I am. Next two to three quarters Will | cj 13 | investorshub | 06/16/2017 1:44:57 AM |
I noticed that $MOC recently closed two contracts | Cboneofenglewood | investorshub | 06/15/2017 12:50:08 PM |
https://seekingalpha.com/article/4075631-command-security-new-contracts-pave-way | cj 13 | investorshub | 05/25/2017 9:50:55 PM |
There is the news we needed. 4mil float.. | cj 13 | investorshub | 05/02/2017 2:44:14 PM |
Hope this bounces off resistance of 2.5. | cj 13 | investorshub | 03/14/2017 12:34:08 AM |
Moc at least has been in a yearly | cj 13 | investorshub | 12/07/2016 3:45:06 PM |
I thought the stock spiked higher on that | hweb2 | investorshub | 11/29/2016 4:46:18 PM |
Why didn't the 10 year 1 billion dollar | cj 13 | investorshub | 11/29/2016 4:42:53 PM |
Saw today's PR. Not surprised the pop | hweb2 | investorshub | 11/29/2016 4:35:46 PM |
4 mil only float. New 50 mil | cj 13 | investorshub | 11/29/2016 4:26:02 PM |
G&T >>>>> 4.18 hod. | crudeoil24 | investorshub | 07/25/2016 1:39:25 PM |
$MOC bullish 3.01 | stocktrademan | investorshub | 07/15/2016 3:50:46 PM |
Wth, is there some toxic financing? How do | cj 13 | investorshub | 06/07/2016 5:41:25 PM |
Imo another 3 days plus of green. | cj 13 | investorshub | 06/06/2016 10:29:18 PM |
Very weird. That $5.73 high was shortly | hweb2 | investorshub | 06/06/2016 8:44:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinic...
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...